Papers - NISHIDA Sachiyo

女性泌尿器科医師の就労・キャリア形成における問題の検討

高橋 さゆり, 中島 のぶよ, 那須 保友, 松下 千枝, 西田 幸代, 前田 佳子, 中川 由紀, 吉川 羊子, 高橋 悟, 赤倉 功一郎, 荒井 陽一, 日本泌尿器科学会男女共同参画委員会

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  103回   679 - 679  2015.04

[Cancer stem cells in prostate cancer].

Sachiyo Nishida, Naoya Masumori

Nihon rinsho. Japanese journal of clinical medicine   72 ( 12 ) 2229 - 33  2014.12  [Domestic journal]

　View Summary

The cancer stem cell (CSC) hypothesis shows that tumors contain a reservoir of self-renewing cells that maintain the tumor. Such cancer cells were first identified in leukemia in the 1990s. These cells appear to be resistant to various therapies and can survive to repopulate the tumor. Therefore, this concept has important therapeutic implications for recurrence and metastasis. In this review, we introduce the CSC hypothesis and the origin, method of identification and functions of prostate CSCs. In addition, we review the therapeutic challenges of targeting prostate CSCs.

PubMed

【去勢抵抗性前立腺癌-基礎と臨床の最新研究動向-】前立腺癌の最新情報 前立腺癌におけるがん幹細胞研究

西田 幸代, 舛森 直哉

日本臨床 ( (株)日本臨床社 )  72 ( 12 ) 2229 - 2233  2014.12

女性泌尿器外科医を支援するために JUA男女共同参画委員会の活動に向けて 女性泌尿器科医支援の新たな展開

中川 由紀, 荒井 陽一, 赤倉 功一郎, 高橋 さゆり, 高橋 悟, 中島 のぶよ, 那須 保友, 西田 幸代, 前田 佳子, 松下 千枝, 吉川 羊子

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  102回   392 - 392  2014.04

ALDH1活性で分離した前立腺癌幹細胞の特徴と成長因子の自己分泌機構

西田 幸代, 廣橋 良彦, 鳥越 俊彦, 田中 俊明, 北村 寛, 舛森 直哉, 佐藤 昇志, 塚本 泰司

泌尿器外科 ( 医学図書出版(株) )  27 ( 2 ) 259 - 259  2014.02

ALDH1活性分析により分離された前立腺癌幹細胞集団の特徴とその遺伝子発現

西田 幸代, 鳥越 俊彦, 廣橋 良彦, 北村 寛, 舛森 直哉, 佐藤 昇志, 塚本 泰司

泌尿器外科 ( 医学図書出版(株) )  26 ( 12 ) 1855 - 1855  2013.12

Autocrine HGF/c-MET signaling in prostate cancer stem-like cells/cancer-initiating cells. Prostate adenocarcinoma tissue was stained by anti-SOX2 and anti-HGF antibodies. HGF is expressed in prostate adenocarcinoma tissue

Sachiyo Nishida, Yoshihiko Hirohashi, Toshihiko Torigoe, Ryuta Inoue, Hiroshi Kitamura, Toshiaki Tanaka, Akari Takahashi, Hiroko Asanuma, Naoya Masumori, Taiji Tsukamoto, Noriyuki Sato

Cancer Science ( Wiley )  104 ( 4 ) April cover - April cover  2013.04

DOI

前立腺がん幹細胞におけるhepatocyte-growth factor(HGF)の自己分泌機構

西田 幸代, 鳥越 俊彦, 廣橋 良彦, 井上 隆太, 田中 俊明, 北村 寛, 高橋 あかり, 舛森 直哉, 塚本 泰司, 佐藤 昇志

日本病理学会会誌 ( (一社)日本病理学会 )  102 ( 1 ) 346 - 346  2013.04

北海道における女性医師支援の現状

西田 幸代

日本泌尿器科学会雑誌 ( (一社)日本泌尿器科学会 )  104 ( 2 ) 182 - 182  2013.03

Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma

Hiroshi Kitamura, Toshihiko Torigoe, Yoshihiko Hirohashi, Hiroko Asanuma, Ryuta Inoue, Sachiyo Nishida, Toshiaki Tanaka, Naoya Masumori, Noriyuki Sato, Taiji Tsukamoto

VIRCHOWS ARCHIV ( SPRINGER )  462 ( 1 ) 101 - 107  2013.01  [Refereed]

　View Summary

Survivin, a member of the inhibitor of apoptosis protein gene family, inhibits apoptosis and promotes mitosis. We determined whether nuclear or cytoplasmic localization of survivin could predict survival of patients with upper urinary tract urothelial carcinoma (UUTUC). Immunohistochemical staining for survivin was carried out on archival specimens from 125 consecutive patients with UUTUC who underwent radical nephroureterectomy. Nuclear and cytoplasmic staining of survivin was scored and compared with clinicopathologic features and cancer-specific survival (CSS). Nuclear expression of survivin was significantly correlated with tumor grade (p<0.001), lymphovascular invasion (p=0.022) and poor survival with an estimated 5-year CSS probability of 54 % for tumors with nuclear expression of survivin vs. 73 % for those without nuclear expression of survivin (hazard ratio=2.19; 95 % confidence interval=1.02-4.70; p=0.043). The 5-year cancer-specific survival rates of patients with cytoplasmic survivin-negative and -positive tumors were 66 and 67%, respectively. There was no difference in survival between patients with cytoplasmic survivin-negative tumors and those with cytoplasmic survivin-positive tumors. Using univariate analysis, nuclear survivin expression, tumor grade, pathological T stage, pathological N stage, and lymphovascular invasion were the predictive variables for CSS. In contrast, cytoplasmic survivin expression had no prognostic relevance. These data suggest that nuclear accumulation of survivin represents biologic aggressiveness and that nuclear survivin is a negative prognostic marker in patients with resected UUTUC.

DOI PubMed

Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract

Hiroshi Kitamura, Toshihiko Torigoe, Yoshihiko Hirohashi, Hiroko Asanuma, Ryuta Inoue, Sachiyo Nishida, Toshiaki Tanaka, Fumimasa Fukuta, Naoya Masumori, Noriyuki Sato, Taiji Tsukamoto

Modern Pathology ( 1 )  26 ( 1 ) 117 - 124  2013.01  [Refereed]

　View Summary

Aldehyde dehydrogenase 1 (ALDH1) and sex determining region-Y-related high mobility group box 2 (SOX2) have been identified as putative cancer stem-like cell/tumor-initiating cell markers in various cancer tissues. The aim of this study was to elucidate the prognostic impact of these putative cancer stem-like cell/tumor-initiating cell markers in upper urinary tract urothelial cell carcinoma. Immunohistochemical staining for ALDH1 and SOX2 was carried out on archival specimens from 125 patients with upper urinary tract urothelial cell carcinoma who underwent radical nephroureterectomy. The prognostic value of ALDH1 and SOX2 expression and other clinicopathological features was evaluated. On univariate analysis, tumor grade, pathological T stage, pathological N stage, lymphovascular invasion, ALDH1 expression and SOX2 expression were associated with a poor prognosis. On multivariate analysis, the independent factors of prognosis were tumor grade (P=0.014), pathological N stage (P=0.005) and ALDH1 expression (P=0.002). In subgroup analysis, those subgroups with no positive, one positive or two positive results in immunohistochemistry for ALDH1 and SOX2 expression had estimated 5-year cancer-specific survival rates of 80%, 49% and 22%, respectively (P< 0.001). Neither ALDH1 nor SOX2 expression correlated with intravesical recurrence after radical nephroureterectomy. These findings suggest that cancer stem-like cells/tumor-initiating cells are linked to more aggressive behavior of upper urinary tract urothelial cell carcinoma, supporting the current cancer stem cell hypothesis. Thus, therapeutic targeting of cancer stem-like cells/tumor-initiating cells in upper urinary tract urothelial cell carcinoma is a future possibility. © 2013 USCAP, Inc.

DOI PubMed

Potential survival benefit of anti-apoptosis protein: Survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer - Results from phase i clinical trials

Toshiaki Tanaka, Hiroshi Kitamura, Ryuta Inoue, Sachiyo Nishida, Akari Takahashi-Takaya, Sachiyo Kawami, Toshihiko Torigoe, Yoshihiko Hirohashi, Taiji Tsukamoto, Noriyuki Sato, Naoya Masumori

Clinical and Developmental Immunology   2013   262967  2013  [Refereed]

　View Summary

We previously identified a human leukocyte antigen (HLA)-A24-restricted antigenic peptide, survivin-2B80-88, a member of the inhibitor of apoptosis protein family, recognized by CD8+cytotoxic T lymphocytes (CTL). In a phase I clinical trial of survivin-2B80-88 vaccination for metastatic urothelial cancer (MUC), we achieved clinical and immunological responses with safety. Moreover, our previous study indicated that interferon alpha (IFNα) enhanced the effects of the vaccine for colorectal cancer. Therefore, we started a new phase I clinical trial of survivin-2B80-88 vaccination with IFNα for MUC patients. Twenty-one patients were enrolled and no severe adverse event was observed. HLA-A24/survivin-2B80-88 tetramer analysis and ELISPOT assay revealed a significant increase in the frequency of the peptide-specific CTLs after vaccination in nine patients. Six patients had stable disease. The effects of IFNα on the vaccination were unclear for MUC. Throughout two trials, 30 MUO patients received survivin-2B80-88 vaccination. Patients receiving the vaccination had significantly better overall survival than a comparable control group of MUO patients without vaccination (P = 0.0009). Survivin-2B80-88 vaccination may be a promising therapy for selected patients with MUC refractory to standard chemotherapy. This trial was registered with UMIN00005859. © 2013 Toshiaki Tanaka et al.

DOI PubMed

腹腔鏡手術の技術向上に経尿道的手術および開放手術の経験はどの程度寄与するか? LapVRを用いて

西田 幸代, 北村 寛, 舛森 直哉, 塚本 泰司

泌尿器外科 ( 医学図書出版(株) )  25 ( 10 ) 2075 - 2075  2012.10

当科における複数の分子標的薬使用経験

西田 幸代, 北村 寛, 高橋 聡, 舛森 直哉, 塚本 泰司

泌尿器外科 ( 医学図書出版(株) )  25 ( 9 ) 1906 - 1906  2012.09

下肢静脈瘤を伴う患者における術前深部静脈超音波検査の意義

西田 幸代, 北村 寛, 高橋 聡, 舛森 直哉, 塚本 泰司

泌尿器外科 ( 医学図書出版(株) )  25 ( 9 ) 1895 - 1895  2012.09

前立腺癌幹細胞におけるHGF autocrineシステム(Prostate cancer stem-like cells/ cancer initiating cells have an autocrine system of Hepatocyte Growth Factor)

西田 幸代, 廣橋 良彦, 鳥越 俊彦, 田中 俊明, 北村 寛, 高橋 あかり, 舛森 直哉, 塚本 泰司, 佐藤 昇志

日本癌学会総会記事 ( 日本癌学会 )  71回   244 - 244  2012.08

ALDH1活性分析により分離された前立腺癌幹細胞集団の特徴とその遺伝子発現

西田 幸代, 鳥越 俊彦, 廣橋 良彦, 北村 寛, 舛森 直哉, 佐藤 昇志, 塚本 泰司

日本泌尿器科学会雑誌 ( (一社)日本泌尿器科学会 )  103 ( 2 ) 461 - 461  2012.03

Prostate cancer detection by prebiopsy 3.0-Tesla magnetic resonance imaging.

Sachiyo Nishida, Hidefumi Kinoshita, Takao Mishima, Hiroaki Kurokawa, Noriko Sakaida, Tadashi Matsuda

International journal of urology : official journal of the Japanese Urological Association   18 ( 9 ) 653 - 8  2011.09  [International journal]

　View Summary

OBJECTIVES: The diagnostic value of 3.0-Tesla magnetic resonance imaging (MRI) for prostate cancer remains to be determined. The aim of the present study was to assess the features of prostate cancer detectable by prebiopsy 3.0-Tesla MRI. METHODS: From January 2007 through to December 2008, 116 patients who were examined by prebiopsy 3.0-Tesla MRI underwent radical prostatectomy for localized prostate cancer. Prostate specimens were examined to see whether the largest cancer area was the same as the area indicated on the MRI. Univariate and multivariate logistic regression analyses were conducted to identify variables predictive of agreement between MRI and histopathological findings. RESULTS: Sixty-six (56.9%) patients were suspected of having prostate cancer on the basis of MRI findings. In 49 of these patients (74.2%), it was considered that there was agreement between the abnormal area on the MRI and the index tumor. Univariate analysis revealed that there were significant differences in abnormal digital rectal examination, capsular penetration, the diameter of the index tumor of the radical prostatectomy specimen, and the Gleason scores of the biopsy and radical prostatectomy specimens. Multivariate analysis revealed that the Gleason score of the radical prostatectomy specimen was associated with the accurate detection of the prostate cancer by MRI (P = 0.0177). CONCLUSIONS: In conclusion, 3.0-Tesla MRI tends to accurately diagnose prostate cancer with high tumor burden and aggressiveness. Multimodal examination (T2-weighted imaging, dynamic contrast-enhanced imaging, and diffusion-weighted imaging) is recommended for the diagnosis of prostate cancer using 3.0-Tesla MRI.

DOI PubMed

ALDH activity assayにより同定された前立腺癌幹細胞の特徴(Prostate cancer stem cells isolated by ALDH activity assay)

西田 幸代, 鳥越 俊彦, 廣橋 良彦, 北村 寛, 舛森 直哉, 塚本 泰司, 佐藤 昇志

日本癌学会総会記事 ( 日本癌学会 )  70回   355 - 355  2011.09

腹腔鏡手術手技に経尿道的および開放手術の経験は寄与するか? 内視鏡手術トレーニングシミュレータを用いて

西田 幸代, 舛森 直哉, 塚本 泰司

Japanese Journal of Endourology ( (一社)日本泌尿器内視鏡学会 )  24 ( 2 ) 289 - 295  2011.09

　View Summary

これまで経尿道的手術や開放手術の経験が腹腔鏡手術手技に役立つか明らかではなかった。当科医師14名(うち腹腔鏡経験なし11名)を対象とし腹腔鏡手術の評価に有用と言われているバーチャルリアリティシステム(VRシステム)を用い各タスク(ペグの移動、カッティング、クリッピング、癒着剥離、胆嚢摘出術)の成績と、過去の経尿道的および開放手術経験数との関係を検討した。1回目では過去の手術経験はVRシステムで評価した腹腔鏡手術手技と関連したため、腹腔鏡手術の開始に当たっては各種手術経験があることが望ましいと考えられた。一方、2回目以降では過去の手術経験数とタスクの成績は相関しなかったため、VRシステムによるトレーニングが過去の経験の少なさを補う可能性があると考えられた。(著者抄録)